Chetan Nayak, MD
Neurology · Roanoke, VANPI 1710408984
Payments from drug & device makers
What this record shows
13 manufacturers reported payments, led by Neuropace, Inc. at 35.9% of the total. Reporting peaked in 2023 at $1,941 and has fallen 83.9% since, to $313 in 2025.
Across 38 payments — averaging $97.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuropace, Inc.$1K
- UCB, Inc.$657
- Ceribell, Inc.$500
- SK Life Science, Inc.$377
- Jazz Pharmaceuticals Inc.$177
- Neurelis, Inc.$168
- plus $497 from 7 others
What the payments were for
- Travel & lodging$1,49940%
- Food & beverage$2,20960%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuropace, Inc. | 5 | $1,333 |
| UCB, Inc. | 12 | $657 |
| Ceribell, Inc. | 1 | $500 |
| SK Life Science, Inc. | 5 | $377 |
| Jazz Pharmaceuticals Inc. | 3 | $177 |
| Neurelis, Inc. | 2 | $168 |
| E.r. Squibb & Sons, L.L.C. | 2 | $134 |
| Greenwich Biosciences, Inc. | 1 | $105 |
| Biogen | 1 | $78 |
| AbbVie | 3 | $58 |
| Sanofi | 1 | $57 |
| KARL Storz Endoscopy-america | 1 | $54 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RNS Neurostimulator Kit$1,159
- POCKET EEG DEVICE$500
- Epidiolex$245
- VALTOCO$110
- Briviact$105
How this compares
$3,708 in reported general payments places this provider in the 65th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 31 | $1,228 |
| Lamotrigine | 24 | $374 |
| Carbamazepine | 14 | $322 |
Paid to pharmacies, not to this prescriber.
Other neurology in Roanoke
- Soundarya Nagaraja GowdaRoanoke$38K
- Ramsey FalconerAlexandria$2M
- Robert ShinCharlottesville$1.7M
- Heidi CraytonVienna$1.5M
- Mark LandrioWinchester$631K
- Catherine HamRichmond$603K
- Jill CramerChristiansburg$598K
- Rahul DaveFairfax$540K
- Daniel HardyRichmond$382K
- Ingrid Loma MillerNorfolk$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.